Sex steroids are known to modulate serum lipoproteins. Studies have suggested that serum testosterone levels are associated with a beneficial lipid profile. Androgen deprivation therapy (ADT) is employed in the treatment of recurrent and metastatic prostate cancer (PCa), resulting in profound hypogonadism. As male hypogonadism unfavorably influences lipid profile and men with PCa have high cardiovascular mortality, we evaluated the effects of long-term ADT on fasting lipids. This Cross-sectional study was conducted in a university-based research institution. We evaluated 44 men, 16 undergoing ADT for at least 12 months before the study (ADT group), 14 age-matched eugonadal men with non-metastatic PCa who were status post prostatectomy and/or radiotherapy and not on ADT (non-ADT group) and 14 age-matched eugonadal controls (Control group). None of the men had known history of diabetes or dyslipidemia. Mean age was similar in the three groups (P ¼ 0.37). Serum total (Po0.01) and free (Po0.01) testosterone levels were lower in the ADT group compared to the other groups. Men on ADT had higher body mass index (BMI) compared to the other groups (Po0.01). Men in the ADT group had significantly higher levels of total cholesterol compared to the other two groups (P ¼ 0.03). After adjustment for BMI, men on ADT continued to have significantly higher fasting levels of total cholesterol (P ¼ 0.02), LDL cholesterol (P ¼ 0.04) and non-HDL cholesterol (P ¼ 0.03) compared to the control group. No significant differences were seen in the levels of other lipoproteins between the three groups. These data show that men undergoing long-term ADT have higher total and LDL cholesterol than age-matched controls. Long-term prospective studies are needed to determine the time of onset of changes in these lipoproteins while on ADT and the influence of these changes on cardiovascular mortality.
Introduction
Sex hormones have been known to influence serum lipids. Epidemiological data suggest that serum total and free testosterone levels are negatively related to total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides levels in non-diabetic men. 1 At the same time, testosterone levels are positively related to serum high-density lipoprotein (HDL) cholesterol. Longitudinal studies have shown that the decline in endogenous serum testosterone levels in men is associated with an increase in serum triglycerides and a decrease in serum HDL levels. 2 These findings are also supported by interventional studies that show that testosterone replacement in hypogonadal men results in an improvement in lipid profiles, especially reductions in triglycerides and LDL levels. 3, 4 Though the levels of HDL also decline, in the majority of the studies, this decline is insignificant.
Prostate cancer (PCa) is one of the most common cancers in men. Local surgery and/or radiotherapy are usually performed in men with locally confined PCa. In men with recurrent or metastatic PCa, androgen deprivation therapy (ADT) is employed with bilateral orchiectomy or gonadotropin releasing hormone (GnRH) analogues. The use of ADT results in castrate testosterone levels. The resulting hypogonadism is responsible for an increase in body mass index (BMI) and fat mass and a decline in lean body mass (LBM), muscle strength, bone density, sexual function, and quality of life. 5 Some studies have evaluated lipid profiles in these men. A recent short-term (3 month) prospective study 6 of ADT did not show any significant changes in lipid profile, while a long-term study (48 week) showed an increase in serum levels of total, HDL and LDL cholesterol and triglycerides. 7 Recently, it has been reported that men with PCa have high cardiovascular mortality. One report showed that cardiovascular disease was the second leading cause of mortality in men with PCa, being responsible for 27% of the deaths. 8 Indeed, men undergoing ADT have been known to have hyperinsulinemia 6 and arterial stiffness, 9 both of which can contribute to cardiovascular mortality. Hence, if men undergoing ADT also have adverse lipid profiles, this would be an additional cardiovascular risk factor in this population.
Using a cross-sectional design, this study evaluates the relationship of lipoproteins in subjects undergoing ADT for PCa and compares them to eugonadal men with PCa not receiving ADT and healthy age-matched eugonadal controls. We hypothesized that after adjusting for BMI, LDL-cholesterol, triglycerides and non-HDL-cholesterol will be elevated, and the HDL-cholesterol will be lower in men on ADT than the two control groups.
Methods

Study design
The study design was cross-sectional. We studied three groups of men: (1) 16 men with PCa who were undergoing ADT (for recurrent or metastatic disease) for at least 12 months before the recruitment for this study (ADT group); (2) 14 age-matched eugonadal men with non-metastatic PCa who had undergone prostatectomy and/or radiotherapy and had not received ADT, but had a rising prostate-specific antigen (PSA) (non-ADT group); (3) 14 age-matched healthy eugonadal (serum testosterone levels 4280 ng/dl) men with a normal PSA (Control group). The average duration of ADT was 45 months (range 12-101 months). Three patients in the ADT group had undergone orchiectomy, whereas the remaining 13 men were on GnRH analogues. All the participants in the ADT group were healthy, had experienced resolution of their metastases on therapy with GnRH analogues and were in remission clinically, radiologically and biochemically. 5 The men in the non-ADT group were generally healthy and were recently found to have biochemical recurrence (rising PSA) but were not yet started on ADT. The men in the non-ADT group had undergone surgery, radiation (XRT) or both at least 12 months before the start of this study ( Table 1 ). The control group comprised of healthy men. None of the patients in any of the groups had known history of diabetes or dyslipidemia and none were on antilipid medications.
The evaluation of men undergoing ADT provided the opportunity to determine the effects of hypogonadism on the lipid profile; the evaluation of non-ADT group allowed us to account for the influence of the cancer itself on serum lipids 10 and the Control group was recruited to account for the lipid changes that may occur with aging. Men in the ADT and non-ADT groups were recruited from the Sydney Kimmel Cancer Center at Johns Hopkins. The control group was recruited from a database of agematched eugonadal men at the Johns Hopkins Hospital Clinical Trials Unit. All men signed informed consent that was approved by the Institutional Review Board of the Johns Hopkins Medical Institutions. Values within a row with different superscripts are significantly different (Po0.05). Abbreviations: ADT, androgen deprivation therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Exclusion criteria
Men were excluded from the analysis if they had any of the following: liver function tests or serum creatinine levels 42 times the upper limit of normal, glucocorticoid use in the previous three months, history of thyroid disease, history of any form of hypogonadism before the diagnosis of PCa and men who had undergone or were currently undergoing cytotoxic chemotherapy.
Hormonal methods
Fasting total testosterone, free testosterone and lipoproteins were measured commercially (Quest Diagnostics, San Juan Capistrano, CA, USA). The normal range for total testosterone was 241-827 ng/ dl and for free testosterone 8-24 ng/dl. Total testosterone was measured by radioimmunoassay with a sensitivity of 20 ng/dl. The intra-and inter-assay coefficients of variation were 6.8 and 8.3%, respectively. The free testosterone was measured by equilibrium dialysis.
Statistical analysis
All the data were analyzed using SAS version 9.1. (SAS Institute Inc., Cary NC, USA). Standard methods were used to compute means and standard errors. Triglycerides were log-transformed to normalize the distribution. One-way ANOVA was used to compare lipid levels among the three groups with Bonferroni's multiple comparison post hoc tests used to compare the mean values. Mean lipid levels were BMI-adjusted and compared using ANCOVA. All significance tests for the comparisons were twosided and P-values below 0.05 were regarded as indicating statistical significance.
Results
Unadjusted data
Unadjusted data are presented in Table 1 . Mean age was similar in the three groups (P ¼ 0.37). Serum total (Po0.01) and free (Po0.01) testosterone levels were significantly lower in the ADT group compared to the other groups. Men in the non-ADT and control groups were eugonadal with no significant difference between their sex hormone levels. Androgen-deprived group had significantly higher BMI than the other two groups (Po0.01). Men in the ADT group had significantly higher serum total cholesterol levels compared to the other groups (P ¼ 0.03). Androgen-deprived men also had higher serum LDL levels compared to the other groups; however, this difference did not achieve statistical significance (P ¼ 0.08). There were no significant differences in the serum levels of HDL and triglycerides between the three groups.
Body mass index adjusted lipid data Body mass index adjusted lipid data is presented in Figure 1 . After adjusting for BMI, men on ADT had higher levels of fasting serum total cholesterol compared to controls (P ¼ 0.02) and the non-ADT group (P ¼ 0.06). Men in the ADT group also had significantly higher LDL cholesterol (P ¼ 0.04) and non-HDL cholesterol (P ¼ 0.03) compared to controls. There were no significant inter-group differences in serum HDL cholesterol, triglycerides or total cholesterol/HDL ratio.
Discussion
Men with PCa undergoing ADT are severely hypogonadal and suffer from adverse effects related to androgen deficiency including reduced LBM and muscle strength, impaired sexual function and quality of life and increased BMI (mainly due to increased fat mass). 5 In addition, hypogonadism is also a risk factor for coronary atherosclerosis 11 and recent evidence suggests that serum testosterone levels positively influence serum lipoproteins. 1 As cardiovascular disorders are known to be a leading cause of death in men with PCa, 12 we determined lipid profile in men who were on long-term ADT and compared them to a group of age-and diseasematched eugonadal men (non-ADT group) and with age-matched eugonadal healthy men (control group). We found that men undergoing ADT had higher levels of fasting total cholesterol compared to the other two groups. After adjustment for BMI, men undergoing ADT continued to have significantly higher serum levels of total cholesterol, LDL cholesterol and non-HDL cholesterol compared to the controls.
Recent evidence suggests that serum testosterone levels in men are negatively associated with LDL and triglycerides and positively related to HDL levels. These associations persist even after adjusting for age, BMI and body fat distribution. 1 In a longitudinal study, the decline in endogenous testosterone level was associated with a significant increase in serum triglycerides even after controlling for BMI and other confounders. 2 Interventional studies have also shown that testosterone replacement in hypogonadal men results in a significant decrease in total cholesterol, LDL cholesterol and triglycerides while serum HDL levels show an insignificant decrease. 3, 4 Some authors believe that this significant decline in 'bad' cholesterol provides a counterbalance to this insignificant decrease in 'good' cholesterol. 4 These beneficial effects of testosterone are thought to be mediated via its aromatization to estrogen. Hence, it is important to differentiate administration of testosterone from administration of non-aromatizable anabolic agents that are known to decrease HDL and increase LDL Lipid profile in hypogonadal men with prostate cancer M Braga-Basaria et al levels. 13 The reason for this difference (in addition to the non-aromatizable nature of these compounds) is that anabolic agents increase hepatic lipase activity, resulting in increased catabolism of HDL. In contrast, testosterone administration results in only a slight increase in the activity of this enzyme.
14 In our study, men on ADT had higher total cholesterol levels than the other groups. As BMI influences serum lipoproteins, 1 we adjusted for this confounder. After adjustment, men on ADT continued to have significantly higher total and LDL cholesterol levels compared to the controls, confirming that these differences were indeed due to hypogonadism. The results did not reach statistical significance against the non-ADT group. This could be due to a smaller sample size, relatively higher BMI in the non-ADT group (compared to controls), elevated cytokine levels or any other putative cancer-related factor in the non-ADT group. Interestingly, we did not observe higher triglyceride levels in the ADT group compared to the other groups, contrary to the studies showing a significant decrease in triglyceride levels in hypogonadal men undergoing androgen replacement. 3 This could be explained by the small sample size of our study.
Previous studies have evaluated lipid profiles in men with PCa. A 3-month prospective study of 22 men showed no significant changes in fasting lipoproteins compared to baseline. 6 Another 3-month prospective study showed that ADT resulted in a significant increase in fasting total and HDL cholesterol; however, there were no changes in LDL and triglycerides levels. 9 Another prospective study in which 49 men with non-metastatic PCa were studied before and 6 months after ADT showed a significant increase in total cholesterol, but no changes in HDL or triglycerides (LDL not reported). 15 The longest prospective study was of 48-week duration in 40 men undergoing ADT. 7 At the end of the study, fasting levels of total cholesterol, Lipid profile in hypogonadal men with prostate cancer M Braga-Basaria et al HDL cholesterol, LDL cholesterol and triglycerides increased by 9, 11.3, 7.3 and 26.5%, respectively. Although our current study was cross-sectional, the duration of ADT in our study was much longer than previous reports (mean duration 45 months, range 12-101 months). We confirm that men on ADT continue to have higher total and LDL cholesterol than age-and disease-matched controls.
Though PCa is one of the leading causes of death in men, approximately half of the men with PCa die of non-cancer-related etiology. Of these, cardiovascular disease is one of the leading causes. Satariano et al. 8 recently showed that deaths due to cardiovascular disease was the second leading cause of death (27% of the deaths). Another report showed that in men with PCa, non-PCa-related deaths now exceed PCa-related mortality, with cardiovascular disease being the single most common cause of nonPCa-related deaths. 12 Indeed, adverse body composition, 5 hyperinsulinemia 6 and arterial stiffness 9 have been documented in men with PCa undergoing ADT, all known risk factors for coronary artery disease. The current study not only confirms that dyslipidemia is an additional cardiovascular risk factor present in this patient population, but provides further impetus to perform longitudinal studies to determine the influence of these adverse lipoprotein profiles on cardiovascular disease. If the harmful effects of hyperlipidemia in this patient population is proven, interventional studies with anti-lipid agents would be the next logical step. Our study has some limitations. First, this is a cross-sectional study and we recommend large prospective studies to evaluate changes in lipoproteins in men undergoing ADT. Second, the majority of men in the three groups were Caucasians. Future studies should include subjects from diverse ethnic backgrounds. Finally, our sample size was small. It is possible that larger sample would have resulted in a significant difference in serum HDL and triglycerides levels between the groups. Our study also has a few strengths. First, the patients were on ADT for a long period of time. This allowed us to evaluate lipoprotein levels in men who had been hypogonadal for a long time. Second, our study included two control groups, that is, men with PCa who were not on ADT and age-matched controls. Finally, none of the participants in the current study had diabetes nor were taking anti-lipid agents. Hence, the lipid levels were not influenced by either of these confounders. To the best of our knowledge, this is the only study that has evaluated lipid profiles in three such groups. This gave us an opportunity to analyze lipid profiles that were likely a direct result of hypogonadism, and independent of age and disease (PCa).
In conclusion, men with PCa undergoing longterm ADT have significantly higher levels of serum total and LDL cholesterol compared to controls. Long-term prospective studies are needed to determine the timing of onset of alterations in lipoprotein levels and their influence on cardiovascular mortality. We suggest that in addition to insulin resistance and arterial stiffness, dyslipidemia should also be regarded as an adverse metabolic consequence of ADT.
